Invasive lobular carcinoma: Response to neoadjuvant letrozole therapy

Breast Cancer Research and Treatment

Volumn 130, Issue 3, 2011, Pages 871-877

  Dixon, J Michael ^a   Renshaw, Lorna ^a   Dixon, Jonathan ^a   Thomas, Jeremy ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Carcinoma; Endocrine; Invasive; Lobular; Neoadjuvant therapy

Indexed keywords

ESTROGEN RECEPTOR; LETROZOLE;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CONTROLLED STUDY; ECHOMAMMOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; INVASIVE LOBULAR CARCINOMA; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; MONOTHERAPY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, LOBULAR; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NITRILES; POSTMENOPAUSE; TREATMENT OUTCOME; TRIAZOLES;

EID: 82255162832     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1735-4     Document Type: Article

References (33)

1. ER Fisher RM Gregorio B Fisher, et al. 1975 The pathology of invasive breast cancer: a syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no 4) Cancer 36 1 85 173455 10.1002/1097-0142(197507)36:1<1::AID-CNCR2820360102>3.0.CO;2-4 1:STN:280:DyaE28%2FptVWhtA%3D%3D
2. V Martinez JG Azzopardi 1979 Invasive lobular carcinoma of the breast: incidence and variants Histopathology 3 467 488 229072 10.1111/j.1365-2559.1979. tb03029.x 1:STN:280:DyaL3c%2FntVKmtA%3D%3D (Pubitemid 10201560)
3. JM Dixon TJ Anderson DL Page, et al. 1982 Infiltrating lobular carcinoma of the breast Histopathology 6 149 161 7076138 10.1111/j.1365-2559.1982.tb02712. x 1:STN:280:DyaL387ovVarsQ%3D%3D (Pubitemid 12150073)
4. RS du Toit AP Locker IO Ellis, et al. 1989 Invasive lobular carcinoma of the breast: the prognosis of histopathological subtypes Br J Cancer 60 605 609 2803932 10.1038/bjc.1989.323 (Pubitemid 19251460)
5. X Sastre-Garau M Jouve B Asselain, et al. 1996 Infiltrating lobular carcinoma of the breast: clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns Cancer 77 113 120 8630916 10.1002/(SICI)1097-0142(19960101)77:1<113::AID-CNCR19>3.0.CO;2-8 1:STN:280:DyaK283itlensg%3D%3D (Pubitemid 26002745)
6. AM Cleton-Jansen 2002 E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res 4 5 8 11879552 10.1186/bcr416 1:CAS:528:DC%2BD38XhsFajtrY%3D (Pubitemid 34097549)
7. WJ de Leeuw G Berx CB Vos, et al. 1997 Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ J Pathol 183 404 411 9496256 10.1002/(SICI)1096-9896(199712)183:4<404::AID- PATH1148>3.0.CO;2-9 (Pubitemid 27509246)
8. Dillon DA, Guidi AJ, Schnitt SJ (2010) Pathology of invasive cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the Breast. Lippincott Williams & Wilkins, Philadelphia, pp 374-407
9. M Cristofanilli A Gonzalez-Angulo N Sneige, et al. 2005 Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes J Clin Oncol 23 41 48 15625359 10.1200/JCO.2005.03.111 (Pubitemid 41702621)
10. MC Mathieu R Rouzier A Llombart-Cussac, et al. 2004 The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile Eur J Cancer 40 342 351 14746851 10.1016/j.ejca.2003.08.015 (Pubitemid 38121270)
11. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer: experience from a large study with long term follow up Histopathology 19 403 410 1757079 10.1111/j.1365-2559.1991.tb00229.x 1:STN:280:DyaK38%2FpvVSltw%3D%3D
12. J Geisler N King G Anker, et al. 1998 In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients Clin Cancer Res 4 2089 2093 9748124 1:CAS:528: DyaK1cXmslCjs70%3D (Pubitemid 28415652)
13. J Geisler B Haynes G Anker, et al. 2002 Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study J Clin Oncol 20 751 757 11821457 10.1200/JCO.20.3.751 1:CAS:528:DC%2BD38XhsVGmt7Y%3D (Pubitemid 34111382)
14. J Geisler H Helle D Ekse, et al. 2008 Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels Clin Cancer Res 14 6330 6335 18829517 10.1158/1078-0432.CCR-07-5221 1:CAS:528:DC%2BD1cXhtF2nurbM
15. JM Dixon L Renshaw O Young, et al. 2008 Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer J Clin Oncol 26 1671 1676 18375896 10.1200/JCO.2007.13.9279 1:CAS:528:DC%2BD1cXltlWhsrk%3D
16. W Eiermann S Paepke J Appfelstaedt, et al. 2001 Letrozole Neo-Adjuvant Breast Cancer Study Group: preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study Ann Oncol 12 1527 1532 11822750 10.1023/A:1013128213451 1:STN:280: DC%2BD38%2FptlGisw%3D%3D (Pubitemid 34065880)
17. MJ Ellis A Coop B Singh, et al. 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 3808 3816 11559718 1:CAS:528: DC%2BD3MXnsVKqsbo%3D (Pubitemid 32880059)
18. JM Dixon L Renshaw EJ Macaskill, et al. 2009 Increase in response rate by prolonged treatment with neoadjuvant letrozole Breast Cancer Res Treat 113 145 151 18264759 10.1007/s10549-008-9915-6 1:CAS:528:DC%2BD1cXhsFWrs7nF
19. The World Health Organization (2003) The World Health Organization classification of tumours-pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon, pp 23-26
20. JM Harvey GM Clark CK Osborne, et al. 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 1474 1481 10334533 1:STN:280:DyaK1M3msFOjsA%3D%3D (Pubitemid 29220854)
21. MM Moore G Borossa JZ Imbrie, et al. 2000 Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy Ann Surg 231 877 882 10816631 10.1097/00000658-200006000-00012 1:STN:280:DC%2BD3c3nslymsA%3D%3D (Pubitemid 30350246)
22. JC Boughey J Wagner BJ Garrett, et al. 2009 Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation Ann Surg Oncol 16 1606 1611 19280264 10.1245/s10434-009-0402-z
23. VF Cocquyt PN Blondeel HT Depypere, et al. 2003 Different responses to preopreative chemotherapy for invasive lobular and invasive ductal breast carcinoma Eur J Surg Oncol 29 361 367 12711290 10.1053/ejso.2002.1404 1:STN:280:DC%2BD3s7pt1eisA%3D%3D (Pubitemid 36675693)
24. LA Newman AU Buzdar SE Singletary, et al. 2002 A prospective trial of preoperative chemotherapy in respectable breast cancer: predictors of breast conservation therapy feasibility Ann Surg Oncol 9 228 234 11923128 10.1007/BF02573059 (Pubitemid 34298626)
25. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
26. MS Moran Q Yang BG Haffty 2009 The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive-ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes and molecular expression of COX-2, Bcl-2 and p53 as a function of histology Breast J 15 571 578 19995377 10.1111/j.1524-4741.2009.00833.x
27. W Domagala M Markiewski Kubiak, et al. 1993 Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative cathepsin D and oestrogen receptor positive Virchows Arch A 423 497 502 10.1007/BF01606541 1:STN:280:DyaK2c7itVOisw%3D%3D
28. PJ Kneeshaw LW Turnbull A Smith, et al. 2003 Dynamic contrast enhanced magnetic resonance imaging aids the surgical management of invasive lobular breast cancer Eur J Surg Oncol 29 32 37 12559074 10.1053/ejso.2002.1391 1:STN:280:DC%2BD3s%2FltVSiug%3D%3D (Pubitemid 36181775)
29. RM Mann YL Hoogeveen JG Blickman, et al. 2008 MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: a review of existing literature Breast Cancer Res Treat 107 1 14 18043894 10.1007/s10549-007-9528-5 (Pubitemid 350179588)
30. J Molland M Donnellan N Janu, et al. 2004 Infiltrating lobular carcinoma-a comparison of diagnosis, management and outcomes with infiltrating duct carcinoma Breast 13 389 396 15454194 10.1016/j.breast.2004.03.004 1:STN:280:DC%2BD2cvosFOisQ%3D%3D (Pubitemid 39549788)
31. R Carpenter JC Doughty CR Wilson, et al. 2010 A multicentre study to determine the optimum duration of neoadjuvant letrozole on tumour regression to permit breast conserving surgery: updated analyses J Clin Oncol 28 670 10.1200/JCO.2010.31.6224 (suppl; abstr 6700)
32. JMJ Dixon L Renshaw J Keys, et al. 2010 Factors affecting local recurrence after breast conserving surgery following neoadjuvant endocrine therapy with letrozole Cancer Res 70 175a 10.1158/1538-7445.AM10-175 (suppl; abstr P1-12-05)
33. JMJ Dixon L Renshaw J Keys, et al. 2010 Outcome of frail, elderly patients treated with letrozole alone Cancer Res 70 175s 176s 10.1158/1538-7445.AM10-175 (suppl; abstr P1-12-06)